ImmunityBio Inc. (26CA)

Profile

https://immunitybio.com

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.